Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Patients With Essential Hypertension.

Trial Profile

Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Patients With Essential Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2012

At a glance

  • Drugs Olmesartan medoxomil; Olmesartan medoxomil/hydrochlorothiazide
  • Indications Essential hypertension; Hypertension
  • Focus Therapeutic Use
  • Sponsors Menarini
  • Most Recent Events

    • 13 Jun 2009 Primary endpoint 'Diastolic blood pressure' has been met.
    • 13 Jun 2009 Results were presented at the 19th European Meeting on Hypertension.
    • 09 Jun 2009 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top